GlassScriptPhysician profile
Abigail L Oliver
NPI 1700218914
$2,057.74
in general payments reported to CMS, 2019-2025
30 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $733 · 2022: $431 · 2023: $270 · 2024: $335 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.28 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.77 | 2021-2025 | |
| Astellas Pharma US INC | $370.34 | 2021-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $273.05 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Argenx US, INC. | $136.90 | 2024-2025 | Vyvgart Hytrulo |
| Lilly USA, LLC | $113.36 | 2021-2023 | Mounjaro |
| Abbott Laboratories | $90.75 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $90.04 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $54.88 | 2022 | |
| Amgen INC. | $52.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $50.33 | 2021-2023 | Xarelto |
| Evofem Biosciences, INC. | $33.03 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $30.72 | 2021 | |
| Seqirus USA INC | $26.78 | 2025 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $25.63 | 2021 | |
| Currax Pharmaceuticals LLC | $25.00 | 2023 | Nexletol |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $24.57 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.08 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $22.26 | 2021 | |
| Eisai INC. | $18.06 | 2021 | |
| Merck Sharp & Dohme LLC | $17.59 | 2022 | |
| Axsome Therapeutics, INC. | $17.40 | 2022 | |
| Avanir Pharmaceuticals, INC. | $17.20 | 2021 | |
| Edwards Lifesciences Corporation | $16.66 | 2022 | |
| Genentech USA, INC. | $15.42 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.04 | 2023 | Quviviq |
| Exact Sciences Corporation | $14.83 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $14.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2024 | Eliquis |
| Pfizer INC. | $13.76 | 2025 | |
| Glaxosmithkline, LLC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.